Baird downgraded Inari Medical (NARI) to Neutral from Outperform with a price target of $80, down from $81, after the company entered into a definitive agreement to be acquired by Stryker (SYK) for $80 per share in cash.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener